Evidence map›Paper›PMID 41621864›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Management of an Allogeneic HSCT Recipient with an SICD during and after Total Body Irradiation.

Akari Matsuoka, Shun-Ichi Kimura, Masakatsu Kawamura, Nozomu Yoshino, Masashiro Saeki, Yusuke Ugata, Masato Suzuki, Keiko Akahane, Takuto Ishikawa, Tomohiro Meno and 13 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Akari MatsuokaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Shun-Ichi KimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Masakatsu KawamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Nozomu YoshinoDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Masashiro SaekiDepartment of Clinical Engineering, Jichi Medical University Saitama Medical Center, Japan.
Yusuke UgataDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan.
Masato SuzukiDepartment of Radiology, Jichi Medical University Saitama Medical Center, Japan.
Keiko AkahaneDepartment of Radiology, Jichi Medical University Saitama Medical Center, Japan.
Takuto IshikawaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Tomohiro MenoDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Yuhei NakamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Shunto KawamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Junko TakeshitaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Yukiko MisakiDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Kazuki YoshimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Ayumi GomyoDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Yosuke OkadaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Masaharu TamakiDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Machiko KusudaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Katsuyuki ShiraiDepartment of Radiology, Jichi Medical University Saitama Medical Center, Japan.
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 19-year-old woman with acute myeloid leukemia who had received a subcutaneous implantable cardioverter defibrillator (SICD) was scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT). The conditioning regimen included total body irradiation (TBI) at a dose of 12 Gy, under which the SICD was considered at high risk for malfunction. We planned to deactivate and reactivate the SICD before and after each TBI session to mitigate the risk of device malfunction. Additionally, SICD shielding measures were implemented during TBI to minimize the risk of malfunction. Through these procedures, HSCT could be performed without significant adverse events linked to the SICD.

Indexed as

Defibrillators, ImplantableHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningWhole-Body IrradiationFemaleHumansTransplantation, HomologousYoung Adultallogeneic hematopoietic stem cell transplantationcardiac implantable electrical devicesimplantable cardioverter defibrillatortotal body irradiationventricular fibrillation

Identifiers

PMID41621864
PMCPMC13627541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.